Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase

The clinical availability of small molecule inhibitors specifically targeting mutated BRAF marked a significant breakthrough in melanoma therapy. Despite a dramatic anti-tumour activity and improved patient survival, rapidly emerging resistance, however, greatly limits the clinical benefit. The majo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosnopfel, Corinna, Sinnberg, Tobias, Sauer, Birgit, Niessner, Heike, Schmitt, Anja, Makino, Elena, Forschner, Andrea, Hailfinger, Stephan, Garbe, Claus, Schittek, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482615/
https://www.ncbi.nlm.nih.gov/pubmed/28415756
http://dx.doi.org/10.18632/oncotarget.16204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482615/
https://www.ncbi.nlm.nih.gov/pubmed/28415756
http://dx.doi.org/10.18632/oncotarget.16204

Ejemplares similares